Recurrence-free Survival as a Surrogate Endpoint for Overall Survival in Resectable Esophageal Cancer: Integrated Analysis of Individual Patient Data From Phase III Trials.

Journal:

Annals of Surgery

Published:

2025-08-26

DOI:

10.1097/sla.0000000000006919

Affiliations:

15

Authors:

20

Go to article

Institutions	Authors	Share
Keio University, Japan	5.000000	0.25
Erasmus University Medical Center (Erasmus MC), Netherlands	2.000000	0.10
Karolinska University Hospital, Sweden	2.000000	0.10
Zhongshan Hospital, Fudan University, China	2.000000	0.10
Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER), France	1.000000	0.05
Keio University Hospital, Japan	1.000000	0.05
Erasmus MC Cancer Institute, Netherlands	1.000000	0.05
Hamamatsu University School of Medicine, Japan	1.000000	0.05
National Cancer Center Hospital, Japan	1.000000	0.05
Shizuoka Cancer Center, Japan	1.000000	0.05
Hôpital Saint-Louis, France	1.000000	0.05
Charité - University Medicine Berlin, Germany	1.000000	0.05
Swiss Group for Clinical Cancer Research (SAKK), Switzerland	0.500000	0.03
University of Basel (UB), Switzerland	0.500000	0.03

Interested in Oncology and Carcinogenesis?